|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.72 USD | -2.42% |
|
-4.87% | -18.26% |
| 03-11 | Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says | MT |
| 03-11 | RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating | MT |
Business description: Legend Biotech Corporation
Number of employees: 2,900
Sales by Activity: Legend Biotech Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology | 91.56M | 117M | 285M | 627M | 1.03B |
Geographical breakdown of sales: Legend Biotech Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States of America | 86.37M | 117M | 270M | 579M | 804M |
outside The United States of America | - | - | - | - | 199M |
China | 3.42M | 328K | 179K | 320K | 26.6M |
Europe | - | - | 15.07M | 47.87M | - |
Other | - | 75K | - | - | - |
Executive Committee: Legend Biotech Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 53 | 20/09/2020 |
Mythili Koneru
CTO | Chief Tech/Sci/R&D Officer | 48 | 10/04/2023 |
Tracy Luo
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/2018 |
Guowei Fang
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/2022 |
Jessie Yeung
DFI | Director of Finance/CFO | 41 | 01/01/2025 |
Composition of the Board of Directors: Legend Biotech Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Ye Wang
CHM | Chairman | 57 | 05/11/2020 |
Ying Huang
BRD | Director/Board Member | 53 | 29/12/2021 |
Corazon Sanders
BRD | Director/Board Member | 69 | 30/04/2020 |
Xiao Hui Ji
BRD | Director/Board Member | 64 | 30/04/2020 |
Wai Man Yau
BRD | Director/Board Member | 50 | 30/04/2020 |
Li Zhu
BRD | Director/Board Member | 76 | 22/11/2020 |
Patrick Casey
BRD | Director/Board Member | 70 | 02/12/2020 |
Fang Liang Zhang
CHM | Chairman | 61 | 26/05/2015 |
Tomas Jan Heyman
BRD | Director/Board Member | 70 | 01/08/2022 |
Li Mao
BRD | Director/Board Member | 69 | 01/08/2022 |
Company details: Legend Biotech Corporation
Bio Therapeutic Drugs
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.42% | -4.87% | -44.66% | -66.57% | 3.36B | |
| -0.73% | +4.38% | +28.37% | +93.71% | 49.79B | |
| -0.58% | +5.72% | +102.90% | +27.47% | 46.97B | |
| -3.10% | -9.05% | +109.74% | +764.15% | 33.42B | |
| +1.95% | +6.76% | -4.78% | -24.84% | 24.15B | |
| -1.73% | +0.86% | +76.93% | -29.37% | 18.97B | |
| +0.31% | +2.51% | +40.93% | -34.28% | 17.25B | |
| -0.29% | -1.92% | +67.64% | +203.86% | 16.25B | |
| +1.47% | +6.69% | -23.69% | +1,146.25% | 15.25B | |
| -1.18% | -3.24% | +61.32% | - | 14.68B | |
| Average | -0.63% | +0.68% | +41.47% | +231.15% | 24.01B | |
| Weighted average by Cap. | -0.65% | +1.91% | +56.02% | +223.22% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LEGN Stock
- Company Legend Biotech Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition